Your donation will make a difference:
Cystic Fibrosis Trust

Administrator - Clinical Trials Accelerator Platform

£27,670 pa if based in Head Office, Central London or £25,300 pa if home-based plus benefits and flexible working

Full time, 35 hours per week

Fixed Term Contract for 18 months, with possibility of renewal

This role is currently based at home and will start at the home-based salary. There will be an option to switch to being Head Office based once our offices fully reopen.

Cystic fibrosis (CF) is a life-shortening inherited condition affecting over 10,600 people in the UK. It is chronically misunderstood, kills thousands worldwide and is carried unknowingly in the genes of millions. We’re here to beat it. With more advances in CF care and treatment than ever before, and a host of new treatments in the pipeline, this is an exciting time for the CF community.

The Clinical Trials Accelerator Platform (CTAP) is a UK-wide initiative bringing together NHS CF centres to support the CF community access and participate in CF clinical trials. The programme is ensuring the UK is at the forefront of the current global efforts to develop life-changing new therapies for people with cystic fibrosis.

In this interesting and varied role, you will be responsible for providing high-level administrative support to the CTAP programme and you will be an important central point of contact for CTAP centre staff alongside internal colleagues. You will also lead in the management of the CF Trials Tracker database and play a critical role in supporting a broad array of workstreams within the CTAP programme. 

Applications are now closed.

Research we fund

We fund research to tackle some of the most pressing issues in CF today. Find out how your donations are making a difference.

What is CF?

Cystic fibrosis, or CF, affects the lungs, digestive system and other organs, and there are over 10,600 people living with it in the UK.

Contact us

Get in touch with us to speak to someone on our Helpline, find out about an event or speak to our Press Team.